| Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy H Farmer, N McCabe, CJ Lord, ANJ Tutt, DA Johnson, TB Richardson, ... Nature 434 (7035), 917-921, 2005 | 7187 | 2005 |
| DNA-repair defects and olaparib in metastatic prostate cancer J Mateo, S Carreira, S Sandhu, S Miranda, H Mossop, R Perez-Lopez, ... New England Journal of Medicine 373 (18), 1697-1708, 2015 | 2254 | 2015 |
| PARP inhibitors: Synthetic lethality in the clinic CJ Lord, A Ashworth Science 355 (6330), 1152-1158, 2017 | 2170 | 2017 |
| The DNA damage response and cancer therapy CJ Lord, A Ashworth Nature 481 (7381), 287-294, 2012 | 1969 | 2012 |
| Political parties in the European Union S Hix, C Lord St. Martin's Press, 1997 | 1572 | 1997 |
| Rethinking ovarian cancer: recommendations for improving outcomes S Vaughan, JI Coward, RC Bast Jr, A Berchuck, JS Berek, JD Brenton, ... Nature Reviews Cancer 11 (10), 719-725, 2011 | 1487 | 2011 |
| Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly (ADP-ribose) polymerase inhibition N McCabe, NC Turner, CJ Lord, K Kluzek, A Białkowska, S Swift, ... Cancer research 66 (16), 8109-8115, 2006 | 1476 | 2006 |
| BRCAness revisited CJ Lord, A Ashworth Nature Reviews Cancer 16 (2), 110-120, 2016 | 1221 | 2016 |
| Legitimacy and the European union D Beetham, C Lord Routledge, 2014 | 1171 | 2014 |
| Resistance to therapy caused by intragenic deletion in BRCA2 SL Edwards, R Brough, CJ Lord, R Natrajan, R Vatcheva, DA Levine, ... Nature 451 (7182), 1111-1115, 2008 | 1082 | 2008 |
| Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors AM Mendes‐Pereira, SA Martin, R Brough, A McCarthy, JR Taylor, JS Kim, ... EMBO molecular medicine 1 (6‐7), 315-322, 2009 | 732 | 2009 |
| Early adaptation and acquired resistance to CDK4/6 inhibition in estrogen receptor–positive breast cancer MT Herrera-Abreu, M Palafox, U Asghar, MA Rivas, RJ Cutts, ... Cancer research 76 (8), 2301-2313, 2016 | 640 | 2016 |
| Germline mutations in RAD51D confer susceptibility to ovarian cancer C Loveday, C Turnbull, E Ramsay, D Hughes, E Ruark, JR Frankum, ... Nature genetics 43 (9), 879-882, 2011 | 603 | 2011 |
| The shieldin complex mediates 53BP1-dependent DNA repair SM Noordermeer, S Adam, D Setiaputra, M Barazas, SJ Pettitt, AK Ling, ... Nature 560 (7716), 117-121, 2018 | 531 | 2018 |
| BMN 673, a novel and highly potent PARP1/2 inhibitor for the treatment of human cancers with DNA repair deficiency Y Shen, FL Rehman, Y Feng, J Boshuizen, I Bajrami, R Elliott, B Wang, ... Clinical Cancer Research 19 (18), 5003-5015, 2013 | 521 | 2013 |
| A decade of clinical development of PARP inhibitors in perspective J Mateo, CJ Lord, V Serra, A Tutt, J Balmaña, M Castroviejo-Bermejo, ... Annals of Oncology 30 (9), 1437-1447, 2019 | 518 | 2019 |
| Genetic interactions in cancer progression and treatment A Ashworth, CJ Lord, JS Reis-Filho Cell 145 (1), 30-38, 2011 | 518 | 2011 |
| Synthetic lethality and cancer therapy: lessons learned from the development of PARP inhibitors CJ Lord, ANJ Tutt, A Ashworth Annual review of medicine 66, 455-470, 2015 | 504 | 2015 |
| Mechanisms of resistance to therapies targeting BRCA-mutant cancers CJ Lord, A Ashworth Nature medicine 19 (11), 1381-1388, 2013 | 475 | 2013 |
| PTEN deficiency in endometrioid endometrial adenocarcinomas predicts sensitivity to PARP inhibitors KJ Dedes, D Wetterskog, AM Mendes-Pereira, R Natrajan, MB Lambros, ... Science translational medicine 2 (53), 53ra75-53ra75, 2010 | 405 | 2010 |
